Polynucleotides encoding human sodium bicarbonate cotransporters

ABSTRACT

The hNBC3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hNBC3 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

FIELD OF THE INVENTION

[0001] This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

BACKGROUND OF THE INVENTION

[0002] The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach as a means to identifying genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

[0003] Functional genomics relies heavily on high throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

SUMMARY OF THE INVENTION

[0004] The present invention relates to hNBC3, in particular hNBC3 polypeptides and hNBC3 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of ischaemic heart disease, arrhythmias, congestive heart disease, stroke and renal ischaemia, hereinafter referred to as “the Diseases”, amongst others In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with hNBC3 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate hNBC3 activity or levels.

DESCRIPTION OF THE INVENTION

[0005] In a first aspect, the present invention relates to hNBC3 polypeptides. Such peptides include isolated polypetides comprising an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid sequence of SEQ ID NO:2. Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2. Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

[0006] In a further aspect, the present invention relates to hNBC3a polypeptides. An hNBCa polypeptide is an alternative form of hNBC which differs in sequence at the N-terminal end of the polypeptide. Such polypeptides may result from alternative splicing of the pre-mRNA transcribed from the hNBC3 gene. The polypeptides of SEQ ID NO:2 (hNBC3) and SEQ ID NO:8 (hNBC3a) are identical from amino acid position 44 (SEQ ID NO:2) and position 32 (SEQ ID NO:8) to the C-terminal end of the respective polypeptides. The difference in the N-terminal sequences arises as a result of an additional 19 bp that are present in the polynucleotide encoding hNBCa, SEQ ID NO:7. In order to translate the hNBC3a polypeptide an alternative start codon is required This alternative start codon may be found at nucleotide position 8-10 in SEQ ID NO:7.

[0007] hNBC3a peptides include isolated polypeptides comprising an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:8 over the entire length of SEQ ID NO:8. Such polypeptides include those comprising the amino acid sequence of SEQ ID NO:8. Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:8 over the entire length of SEQ ID NO:8. Such polypeptides include the polypeptide of SEQ ID NO:8. Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:7.

[0008] Polypeptides of the present invention are believed to be members of the sodium bicarbonate cotransporter family of polypeptides. They are therefore of interest because the Na+/HCO3-transporter (sodium-bicarbonate transporter ie. NBC), is one of the mechanisms involved in the regulation of intracellular pH. Acidosis established during myocardial ischemia stimulates NBC: extrusion of protons through NBC and is accompanied by cellular uptake of Na+, leading to more dangerous Ca2+overload due to the functioning of Na+/Ca2+exchanger in reverse-mode. This implies that specific inhibition of NBC will be of benefit in reduction of cellular injury during ischaemia. These properties of the hNBC3 and hNBC3a polypeptides are hereinafter referred to as “hNBC3 activity” or “hNBC3 polypeptide activity” or “biological activity of hNBC3”. Also included amongst these activities are antigenic and immunogenic activities of said hNBC3 polypeptides, in particular the antigenic and immunogenic activities of the polypeptide of SEQ ID NO:2 or SEQ ID NO:8. Preferably, a polypeptide of the present invention exhibits at least one biological activity of hNBC3.

[0009] The polypeptides of the present invention may be in the form of the “mature” protein or may be a part of a larger protein such as a precursor or fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

[0010] The present invention also includes include variants of the aforementioned polypetides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

[0011] Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

[0012] In a further aspect, the present invention relates to hNBC3 polynucleotides. The polynucleotide of SEQ ID NO:1 encodes the hNBC3 polypeptide and the polynucleotide of SEQ ID NO:7 encodes the hNBC3a polypeptide. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, over the entire length of SEQ ID NO:2 or SEQ ID NO:8. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:2 and a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:7 encoding the polypeptide of SEQ ID NO:8.

[0013] Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:8, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to SEQ ID NO:1 or SEQ ID NO:7 over the entire length of SEQ ID NO:1 or SEQ ID NO:7. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:7 as well as the polynucleotides of SEQ ID NO:1 and SEQ ID NO:7.

[0014] The invention also provides polynucleotides which are complementary to all the above described polynucleotides.

[0015] The nucleotide sequences of SEQ ID NO:1 and SEQ ID NO:7 show homology with human kidney Na+/HCO3− cotransporter (E. Burnham et al. J Biol Chem.272: 19111-19117, 1997). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and encodes a polypeptide of SEQ ID NO:2 that has homology to Human kidney Na+/HCO3− cotransporter. The nucleotide sequence of SEQ ID NO:7 is a cDNA sequence and encodes a polypeptide of SEQ ID NO:8 that has homology to Human kidney Na+/HCO3− cotransporter. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:8 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or SEQ ID NO:7 or it may be a sequence other than the one contained in SEQ ID NO:1 or SEQ ID NO:7, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2 or SEQ ID NO:8. The polypeptides of SEQ ID NO:2 and SEQ ID NO:8 are structurally related to other proteins of the sodium bicarbonate cotransporter family, having homology and/or structural similarity with Human kidney Na+/HCO3− cotransporter (E. Burnham et al. J Biol Chem.272: 19111-19117, 1997)..

[0016] Preferred polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one hNBC3 activity.

[0017] The present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:2 and SEQ ID NO:8.

[0018] Accordingly, in a further aspect, the present invention provides for an isolated polynucleotide which:

[0019] (a) comprises a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

[0020] (b) has a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

[0021] (c) the polynucleotide of SEQ ID NO:3; or

[0022] (d) a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4; as well as the polynucleotide of SEQ ID NO:3.

[0023] (e) comprises a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity to SEQ ID NO:5 or SEQ ID NO:9 over the entire length of SEQ ID NO:5 or SEQ ID NO:9;

[0024] (f) has a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to SEQ ID NO:5 or SEQ ID NO:9 over the entire length of SEQ ID NO:5 or SEQ ID NO:9;

[0025] (g) the polynucleotide of SEQ ID NO:5 or SEQ ID NO:9; or

[0026] (h) a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:10, over the entire length of SEQ ID NO:6 or SEQ ID NO:10; as well as the polynucleotides of SEQ ID NO:5 and SEQ ID NO:9.

[0027] The present invention further provides for a polypeptide which:

[0028] (a) comprises an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;

[0029] (b) has an amino acid sequence which is at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;

[0030] (c) comprises the amino acid of SEQ ID NO:4; and

[0031] (d) is the polypeptide of SEQ ID NO:4; as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

[0032] (e) comprises an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:6 or SEQ ID NO:10 over the entire length of SEQ ID NO:6 or SEQ ID NO:10;

[0033] (f) has an amino acid sequence which is at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:10 over the entire length of SEQ ID NO:6 or SEQ ID NO:10;

[0034] (c) comprises the amino acid of SEQ ID NO:6 or SEQ ID NO:10; and

[0035] (d) is the polypeptide of SEQ ID NO:6 or SEQ ID NO:10; as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:5 or SEQ ID NO:9.

[0036] The nucleotide sequences of SEQ ID NO:5 and SEQ ID NO:9 and the peptide sequence encoded thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognised by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see Adams, M.D. et al, Nature 377 (supp) 3, 1995). Accordingly, the nucleotide sequences of SEQ ID NO:5 and SEQ ID NO:9 and the peptide sequence encoded therefrom are therefore subject to the same inherent limitations in sequence accuracy.

[0037] Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human keratinocyte, thymus, leucocyte and brain, using the expressed sequence tag (EST) analysis (Adams, M.D., et al. Science (1991) 252:1651-1656; Adams, M. D. et al., Nature, (1992) 355:632-634; Adams, M. D., et al., Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

[0038] When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5′ and 3′ sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

[0039] Further embodiments of the present invention include polynucleotides encoding polypeptide variants which comprise the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.

[0040] Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1 or SEQ ID NO:7, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1 or SEQ ID NO:7. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that of the referent. The probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

[0041] A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or SEQ ID NO:7 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42° C. in a solution comprising: 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1× SSC at about 65° C. Thus the present invention also includes polynucleotides obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1, SEQ ID NO:7 or a fragment thereof.

[0042] The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is cut short at the 5′ end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low ‘processivity’ (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.

[0043] There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an ‘adaptor’ sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the ‘missing’ 5′ end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using ‘nested’ primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3′ in the adaptor sequence and a gene specific primer that anneals further 5′ in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5′ primer.

[0044] Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression sytems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

[0045] For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

[0046] Representative examples of appropriate hosts include bacterial cells, such as Streptococci, Staphylococci, E. coli, Streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

[0047] A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (supra). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

[0048] If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

[0049] Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

[0050] This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 or SEQ ID NO:7 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

[0051] Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled hNBC3 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (ee, e.g., Myers et al., Science (1985)230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton et al., Proc Natl Acad Sci USA (1985) 85:

[0052]4397-4401). In another embodiment, an array of oligonucleotides probes comprising hNBC3 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M. Chee et al., Science, Vol 274, pp 610-613 (1996)).

[0053] The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the hNBC3 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

[0054] Thus in another aspect, the present invention relates to a diagonostic kit which comprises:

[0055] (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:7 or a fragment thereof;

[0056] (b) a nucleotide sequence complementary to that of (a);

[0057] (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2, SEQ ID NO:8 or a fragment thereof; or

[0058] (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2 or SEQ ID NO:8.

[0059] It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or suspectability to a disease, particularly ischaemic heart disease, arrhythmias, congestive heart disease, stroke or renal ischaemia, amongst others.

[0060] The nucleotide sequences of the present invention are also valuable for chromosomal localisation. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

[0061] The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

[0062] The nucleotide sequences of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the hNBC3 polypeptides in tissues by detection of the mRNAs that encode them. These techniques include in situ hybridziation techniques and nucleotide amplification techniques, for example PCR. Such techniques are well known in the art. Results from these studies provide an indication of the normal functions of the polypeptides in the organism. In addition, comparative studies of the normal expression pattern of hNBC3 mRNAs with that of mRNAs encoded by a mutant hNBC3 gene provide valuable insights into the role of mutant hNBC3 polypeptides, or that of inappropriate expression of normal hNBC3 polypeptides, in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

[0063] The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term “immunospecific” means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

[0064] Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozboret al., Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al., MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

[0065] Techniques for the production of single chain antibodies, such as those described in U.S. Pat. No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

[0066] The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

[0067] Antibodies against polypeptides of the present invention may also be employed to treat the Diseases, amongst others.

[0068] In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

[0069] Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned amongst others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases.

[0070] A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide of the present invention The vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation instonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

[0071] Polypeptides of the present invention are responsible for one or more biological functions, including one or more disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirous to devise screening methods to identify compounds which stimulate or which inhibit the function of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists, antagonists or inhibitors so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991)).

[0072] The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring hNBC3 activity in the mixture, and comparing the hNBC3 activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and hNBC3 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett et al., J Mol Recognition, 8:52-58 (1995); and K. Johanson et al., J Biol Chem, 270(16):9459-9471 (1995)).

[0073] Screening methods include those involving the measurement of changes in intracellular pH Methods in which intracellular pH recovery after an intracellular acidification is recorded using specific fluorescent dye or microphysiometer method are particularly preferred.

[0074] The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide(also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

[0075] The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ¹²⁵I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

[0076] Examples of potential polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypetide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

[0077] Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises:

[0078] (a) a polypeptide of the present invention;

[0079] (b) a recombinant cell expressing a polypeptide of the present invention;

[0080] (c) a cell membrane expressing a polypeptide of the present invention; or

[0081] (d) antibody to a polypeptide of the present invention;

[0082] which polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:8.

[0083] It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

[0084] It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by:

[0085] (a) determining in the first instance the three-dimensional structure of the polypeptide;

[0086] (b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist, antagonist or inhibitor;

[0087] (c) synthesing candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and

[0088] (d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors.

[0089] It will be further appreciated that this will normally be an iterative process.

[0090] In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, ischaemic heart disease, arrhythmias, congestive heart disease, stroke or renal ischaemia, related to either an excess of, or an under-expression of, hNBC3 polypeptide activity.

[0091] If the activity of the polypeptide is in excess, several approaches are available. One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the hNBC3 polypeptide.

[0092] In still another approach, expression of the gene encoding endogenous hNBC3 polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or externally administered (see, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). Alternatively, oligonucleotides which form triple helices (“triplexes”) with the gene can be supplied (see, for example, Lee et al., Nucleic Acids Res (1979) 6:3073; Cooney et al., Science (1988) 241:456; Dervan et al, Science (1991)251:1360). These oligomers can be administered per se or the relevant oligomers can be expressed in vivo. Synthetic antisense or triplex oligonucleotides may comprise modified bases or modified backbones. Examples of the latter include methylphosphonate, phosphorothioate or peptide nucleic acid backbones. Such backbones are incorporated in the antisense or triplex oligonucleotide in order to provide protection from degradation by nucleases and are well known in the art. Antisense and triplex molecules synthesised with these or other modified backbones also form part of the present invention.

[0093] In addition, expression of the hNBC3 polypeptide may be prevented by using ribozymes specific to the hNBC3 mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, et al., Curr. Opin. Struct. Biol (1996) 6(4), 527-33.) Synthetic ribozymes can be designed to specifically cleave hNBC3 mRNAs at selected positions thereby preventing translation of the hNBC3 mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribosymes may be synthesised with non-natural backbones to provide protection from ribonuclease degradation, for example, 2′-O-methyl RNA, and may contain modified bases.

[0094] For treating abnormal conditions related to an under-expression of hNBC3 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of hNBC3 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

[0095] In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

[0096] The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

[0097] The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 μg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

[0098] Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as “gene therapy” as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

[0099] Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as those in the GCG and Lasergene software packages. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO:1 and/or a polypeptide sequence encoded thereby.

[0100] The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

[0101] “Antibodies” as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

[0102] “Isolated” means altered “by the hand of man” from the natural state. If an “isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.

[0103] “Polynucleotide” generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single-and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term “polynucleotide” also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short polynucleotides, often referred to as oligonucleotides.

[0104] “Polypeptide” refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. “Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, PROTEINS—STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter et al., “Analysis for protein modifications and nonprotein cofactors”, Meth Enzymol (1990) 182:626-646 and Rattan et al., “Protein Synthesis: Post-translational Modifications and Aging”, Ann NY Acad Sci (1992) 663:48-62).

[0105] “Variant” refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

[0106] “Identity” is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. “Identity” per se has an art-recognized meaning and can be calculated using published techniques (see, e.g.: COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A. M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D. W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term “identity” is well known to skilled artisans (Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research (1984) 12(1):387), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., J Molec Biol (1990) 215:403).

[0107] By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the numerical percent of the respective percent identity(divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

n_(n)≦X_(n)−(x_(n)•y),

[0108] wherein n_(n) is the number of nucleotide alterations, x_(n) is the total number of nucleotides in SEQ ID NO:1, and y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and wherein any non-integer product of x_(n) and y is rounded down to the nearest integer prior to subtracting it from x_(n). Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

[0109] Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the numerical percent of the respective percent identity(divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

n_(a)≦x_(a)−(x_(a)•y),

[0110] wherein n_(a) is the number of amino acid alterations, x_(a) is the total number of amino acids in SEQ ID NO:2, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x_(a) and y is rounded down to the nearest integer prior to subtracting it from x_(a).

[0111] “Homolog” is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described.

[0112] Falling within this generic term are the terms “ortholog”, meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and “paralog” meaning a functionally similar sequence when considered within the same species. Hence in the rat, for example, a member of the family of serotonin receptors is a paralog of the other members of the rat serotonin receptor family.

[0113] “Fusion protein” refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

[0114] All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

[0115] SEQUENCE INFORMATION TTGGCTTGGAGCCCGTGGGGGAGACCTAGTTCGGCTCCGCCATGCCGGCCGCCGGGAGTAACGAGCCGGACGGCGTCCTC SEQ ID NO:1 AGCTATCAGAGACCAGATGAAGAAGCTGTGGTGGATCAGGGTGGGACCAGTACAATTCTCAACATTCACTATGAAAAAGA AGAGCTGGAAGGTCACAGAACTCTGTATGTGGGAGTTCGGATGCCGCTTGGCCGGCAGAGCCATCGGCATCACCGCACTC ATGGCCAGAAGCACCGGAGACGAGGGCGGGGCAAAGGAGCCAGCCAGGGGGAGGAAGGCCTGGAAGCCCTGGCCCACGAC ACACCATCTCAGCGTGTTCAGTTCATTCTTGGCACCGAGGAAGATGAAGAGCATGTGCCTCATGAGCTGTTTACAGAGCT GGATGAGATCTGTATGAAAGAGGGAGAAGATGCTGAGTGGAAGGAAACAGCCAGGTGGCTGAAGTTTGAAGAAGATGTTG AAGATGGGGGAGAACGCTGGAGCAAGCCTTATGTGGCAACCCTTTCATTGCACAGCCTGTTTGAGCTAAGGAGCTGCCTT ATTAATGGAACAGTCCTCCTGGATATGCATGCAAATAGCATAGAAGAAATTTCAGACCTGATCCTGGATCAGCAAGAACT GTCCAGTGACCTGAATGACAGCATGAGGGTTAAAGTGCGGGAAGCCCTTCTCAAAAAGCATCATCATCAGAATGAAAAGA AGAGAAACAACCTCATTCCCATTGTTCGCTCCTTTGCTGAGGTTGGCAAGAAGCAGTCTGATCCTCATTTGATGGATAAA CATGGTCAAACCGTGTCTCCTCAGTCTGTTCCAACTACAAATCTTGAAGTAAAAAATGGAGTGaATTGTGAACATAGTCC TGTGGATTTAAGCAAGGTAGACCTTCATTTCATGAAAAAAATTCCTACTGGGGCCGAGGCCTCCAATGTCCTGGTTGGAG AGGTGGATATTTTGGACCGTCCCATTGTTGCCTTTGTGAGGCTGTCTCCAGCTGTTCTTCTCTCAGGCCTAACAGAAGGT CCAATCCCAACAAGATTTTTGTTTATCTTATTGGGTCCAGTAGGGAAAGGTCAGCAGTACCATGAGATTGGCAGATCCAT GGCCACCATCATGACAGATGAGATTTTTCATGACGTAGCATATAAGGCAAAAGAGCGAGATGATCTCCTGGCGGGGATTG ATGAGTTCCTAGACCAGGTGACGGTGCTCCCTCCAGGAGAGTGGGATCCCTCCATTAGAATTGAGCCACCCAAAAATGTC CCTTCCCAGGAGAAAAGGAAAATGCCTGGAGTTCCAAATGGAAATGTTTGCCACATAGAACAGGAACCACATGGGGGTCA CAGTGGGCCAGAACTTCAGCGCACTGGGCGGCTATTTGGGGGCTTGGTGCTGGACATCAAGCGGAAGGCCCCCTGGTACT GGAGCGACTACCGAGATGCACTCAGCTTACAGTGTTTGGCTTCCTTTCTGTTCCTGTACTGTGCCTGCATGTCACCTGTC ATCACCTTTGGGGGACTGCTTGGAGAAGCCACTGAGGGACGCATAAGTGCAATTGAATCCTTGTTTGGAGCTTCCATGAC TGGGATTGCTTATTCCTTGTTTGCGGGACAGGCTCTCCACCATCTGGGAAGTACTGGACCAGTGCTTGTGTTTGAAAAGA TTTTGTTCAAATTCTGCAAAGACTATGCTCTTTCATACCTCTCCCTGCGAGCTTGTATTGGACTGTGGACCGCTTTCCTG TGTATTGTCCTTGTGGCAACTGATGCCAGTTCCCTTGTCTGCTACATTACCCGTTTCACTGAAGAAGCATTTGCCTCCCT AATTTGCATTATTTTCATCTATGAAGCAATAGAAAAACTGATTCACCTGGCAGAGACCTACCCCATCCAAATGCACAGCC AGCTGGACCACCTTAGCCTCTATTACTGCAGGTGTACTCTGCCAGAGAATCCAAACAATCACACCCTCCAGTACTGGAAG GACCACAACATCGTGACAGCAGAAGTCCACTGGGCTAACCTGACTGTCAGTGAATGCCAGGAGATGCATGGAGAGTTCAT GGGATCTGCGTGCGGCCATCATGGACCCTACACTCCTGATGTCCTCTTTTGGTCCTGTATTCTCTTTTTCACCACCTTCA TCCTCTCAAGCACCTTAAAGACGTTTAAGACGAGCCGTTATTTCCCAACCAGAGTACGCTCCATGGTGAGTGACTTTGCT GTTTTCCTCACTATCTTCACAATGGTGATTATTGATTTTTTGATTGGAGTCCCATCACCAAAGCTTCAAGTTCCCAGTGT GTTCAAGCCAACAAGGGATGATCGCGGATGGATTATTAATCCCATTGGCCCCAATCCCTGGTGGACTGTGATAGCTGCAA TTATCCCAGCTCTTCTCTGTACTATCTTGATATTCATGGATCAGCAGATCACAGCCGTCATTATTAACAGGAAGGAACAT AAGCTCAAGAAAGGCTGTGGCTACCACCTGGACCTACTGATGGTGGCCATCATGCTGGGTGTCTGCTCCATCATGGGCCT GCCCTGGTTTGTAGCTGCAACTGTCTTGTCCATCACACATGTGAACAGCCTCAAGCTAGAATCTGAATGCTCTGCTCCTG GAGAACAGCCCAAGTTCCTGGGCATCCGAGAACAGAGAGTGACAGGCCTTATGATCTTTGTGCTGATGGGCTGCTCAGTC TTCATGACGGCTATCTTAAAGTTTATTCCAATGCCAGTACTCTACGGAGTTTTCCTTTACATGGGAGTTTCTTCACTACA GGGAATTCAGTTCTTTGATCGTCTAAAGCTCTTTGGGATGCCCGCAAAGCACCAGCCAGATTTCATCTACCTGCGGCATG TGCCGCTGCGCAAAGTGCACCTCTTCACCCTCATCCAGTTGACCTGTCTCGTCCTGCTCTGGGTCATCAAGGCATCTCCA GCTGCCATTGTTTTCCCAATGATGGTTTTGGCCTTGGTCTTTGTCAGGAAAGTCATGGATCTCTGTTTCTCTAAGCGAGA GCTGAGCTGGCTAGATGATCTCATGCCTGAAAGCAAAAAGAAGAAGTTGGATGATGCCAAAAAGAAGGCCAAGGAGGAAG AGGTCATAGTCCTTGCACCAACTGTATACCTGGGGGCCTCAAATTACAGAACATAGGAAGGGTCATGTGAAAAGTCAGCA TGTCTGGAATCCCGAGGGTTATATTTAGGAGCTGGGAAGATTACCCCCAAAGATGTTCTCAGCTAAGAATGGATTAGGGA TTCTTGCTTCTGTCTGTTCTTAATTTTTGGGTTTGACAACCACTTATTTTTTCCTTTGTTTACAATCTACTCACCAGGCT CATACCTACAATGTGAACATACAGTATGCCCTTATTAGCAGATTCAATGGCTCACATTCTTTCAAAAGGTCTAATTTGAC AAATACATAAGACCCATTATTTCCTAGAATGTTTGTAATATATCTAATTGCAAATGGTGCTGTGGTTGGCACCATGCAAA GATAACTTGCATAGGACTTTCTGTCTTTTTTCATTTCCCTCAGCATTTGGCATCTTGTCATCTACACAATGGACCCTCAA TAAATGGCCTATATGTGCAAAGAAAGAATGTGTAGCAAATGAAAATACCAGACCAAGAAATGAGTGAGCTGGGAAGTGTT TCCAAATACAGTTAGTGCCTAAAATAGTGTCCTTTGAAAAAACTTTTAAAAGACTTTTTTTTAGGCCAGGCATAATGGGT TATCCCTGTAATTCCAGGGCTTTTGGGAGTTGAAGCTGGAGGATTACTTGAGGCCAGAAGTTTGAGACTAGCCTAGGCAA TATAATGAGACCCTGTCTCTACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA MPAAGSNEPDGVLSYQRPDEEAVVDQGGTSTILNIHYEKEELEGHRTLYVGVRMPLGRQSHRHHRTHGQKHRRRGRGKGA SEQ ID NO:2 SQGEEGLEALAHDTPSQRVQFILGTEEDEEHVPHELFTELDEICMKEGEDAEWKETARWLKFEEDVEDGGERWSKPYVAT LSLHSLFELRSCLINGTVLLDMHANSIEEISDLILDQQELSSDLNDSMRVKVREALLKKHHHQNEKKRNNLIPIVRSFAE VGKKQSDPHLMDKHGQTVSPQSVPTTNLEVKNGVNCEHSPVDLSKVDLHFMKKIPTGAEASNVLVGEVDILDRPIVAFVR LSPAVLLSGLTEVPIPTRFLFILLGPVGKGQQYHEIGRSMATIMTDEIFHDVAYKAKERDDLLAGIDEFLDQVTVLPPFE WDPSIRIEPPKNVPSQEKRKMPGVPNGNVCHIEQEPHGGHSGPELQRTGRLFGGLVLDIKRKAPWYWSDYRDALSLQCLA SFLFLYCACMSPVITFGGLLGEATEGRISAIESLFGASMTGIAYSLFAGQALTILGSTGPVLVFEKILFKFCKDYALSYL SLRACIGLWTAFLCIVLVATDASSLVCYITRFTEEAFASLICIIFIYEAIEKLIHLAETYPIQMHSQLDHLSLYYCRCTL PENPNNHTLQYWKDHNIVTAEVHWANLTVSECQEMHGEFMGSACGHHGPYTPDVLFWSCILFFTTFILSSTLKTFKTSRY FPTRVRSMVSDFAVFLTIFTMVIIDFLIGVPSPKLVQPSVFKPTRDDRGWIINPIGPNPWWTVIAAIIPALLCTILIFMD QQITAVIINRKEHKLKKGCGYHLDLLMVAIMLGVCSIMGLPWFVAATVLSITHVNSLKLESECSAPGEQPKFLGIREQRV TGLMIFVLMGCSVFMTAILKFIPMPVLYGVFLYMGVSSLQGIQFFDRLKLFGMPAKHQPDFIYLRHVPLRKVHLFTLIQL TCLVLLWVIKASPAAIVFPMMVLALVFVRKVMDLCFSKRELSWLDDLMPESKKKKLDDAKKKAKEEEVIVLAPTVYLGAS NYRT ACAGAAGTGCCAATCCCAACAAGATTTTTGTTTATCTTATTGGGTCCAGTAGGGAAAGGTCAGCAGTACCATGAGATTGG SEQ ID NO:3 CAGATCCATGGCCACCATCATGACAGATGAGATTTTTCATGACGTAGCATATAAGGCAAAAGAGCGAGATGATCTCCTGG CGGGGATTGATGAGTTCCTAGACCAGGTGACGGTGCTCCCTCCAGGAGAGTGGGATCCCTCCATTAGAATTGAGCCACCC AAAAATGTCCCTTCCCAGGAGAAAAGGAAAATGCCTGGAGTTCCAAATGGAAATGTTTGCCACATAGAACAGGAACCACA TGGGGGTCACAGTGGGCCAGAACTTCAGCGCACTGGGCGGCTATTTGGGGGCTTGGTGCTGGACATCAAGCGGAAGGCCC CCTGGTACTGGAGCGACTACCGAGATGCACTCAGCTTACAGTGTTTGGCTTCCTTTCTGTTCCTGTACTGTGCCTGCATG TCACCTGTCATCACCTTTGGGGGACTGCTTGGAGAAGCCACTGAGGGACGCATAAGTGCAATTGAATCCTTGTTTGGAGC TTCCATGACTGGGATTGCTTATTCCTTGTTTGCGGGACAGGCTCTCACCATCCTGGGAAGTACTGGACCAGTGCTTGTGT TTGAAAAGATTTTGTTCAAATTCTGCAAAGACTATGCTCTTTCATACCTCTCCCTGCGAGCTTGTATTGGACTGTGGACC GCTTTCCTGTGTATTGTCCTTGTGGCAACTGATGCCAGTTCCCTTGTCTGCTACATTACCCGTTTCACTGAAGAAGCATT TGCCTCCCTAATTTGCATTATTTTCATCTATGAAGCAATAGAAAAACTGATTCACCTGGCAGAGACCTACCCCATCCACA TGCACAGCCAGCTGGACCACCTTAGCCTCTATTACTGCAGGTGTACTCTGCCAGAGAATCCAAACAATCACACCCTCCAG TACTGGAAGGACCACAACATCGTGACAGCAGAAGTCCACTGGGCTAACCTGACTGTCAGTGAATGCCAGGAGATGCATGG AGAGTTCATGGGATCTGCGTGCGGCCATCATGGACCCTACACTCCTGATGTCCTCTTTTGGTCCTGTATTCTCTTTTTCA CCACCTTCATCCTCTCAAGCACCTTAAAGACGTTTAAGACGAGCCGTTATTTCCCAACCAGAGTACGCTCCATGGTGAGT GACTTTGCTGTTTTCCTCACTATCTTCACAATGGTGATTATTGATTTTTTGATTGGAGTCCCATCACCAAAGCTTCAAGT TCCCAGTGTGTTCAAGCCAACAAGGGATGATCGCGGATGGATTATTAATCCCATTGGCCCCAATCCCTGGTGGACTGTGA TAGCTGCAATTATCCCAGCTCTTCTCTGTACTATCTTGATATTCATGGATCAGCAGATCACAGCCGTCATTATTAACAGG Gene Name F52B5.1 [Caenorhabditis elegans] Strand Score 387 Bits 179.3 Query Seq Start 262 End 351 Length 90 Blase Poisson Probability 3.2e-48 DB Seq Start 3 End 272 Length 270 Identity 68/90 = 75.56% Positives 82/90 = 91.11% Relative Position of Alignment: 1 |=========================================================================|970  Q: 262 TEVPVPTRFLFILLGPKGKAKSYHEIGRSIATLMSDEVFHDIAYKAKNREDLIAGIDEFL 321         TEVP+PTRFLFILLGP GK + YHEIGRS+AT+M+DE+FHD+ YKAK R+DL +AGIDEFL DB:   3 TEVPIPTRFLFILLGPVGKGQQYHEIGRSMATIMTDEIFHDVXYKAKERDDLLAGIDEFL 182 DB: 322 DEVIVLPLGEWDPTIRIEPPKSLPSSDKRK 351         D+V VLP GEWDP+IRIEPPK++PS +KRK DB: 183 DQVTVLPPGEWDPSIRIEPPKNVPSQEKRK 272 SEQ ID NO:6 refers to the sequence labelled ‘Q’ AGACCAGATGAAGAAGCTGTGGTGGATCAGGGTGGGACCAGTACAATTCTCAACATTCACTATGAAAAAGAAGAGCTGGA SEQ ID NO:7 AGACCTTCTGCTTCTTTCCAGGTCACAGAACTCTGTATGTGGGAGTTCGGATGCCGCTTGGCCGGCAGAGCCATCGGCAT CACCGCACTCATGGCCAGAAGCACCGGAGACGAGGGCGGGGCAAAGGAGCCAGCCAGGGGGAGGAAGGCCTGGAAGCCCT GGCCCACGACACACCATCTCAGCGTGTTCAGTTCATTCTTGGCACCGAGGAAGATGAAGAGCATGTGCCTCATGAGCTGT TTACAGAGCTGGATGAGATCTGTATGAAAGAGGGAGAAGATGCTGAGTGGAAGGAAACAGCCAGGTGGCTGAAGTTTGAA GAAGATGTTGAAGATGGGGGAGAACGCTGGAGCAAGCCTTATGTGGCAACCCTTTCATTGCACAGCCTGTTTGAGCTAAG GAGCTGCCTTATTAATGGAACAGTCCTCCTGGATATGCATGCAAATAGCATAGAAGAAATTTCAGACCTGATCCTGGATC AGCAAGAACTGTCCAGTGACCTGAATGACAGCATGAGGGTTAAAGTGCGGGAAGCCTTCTCAAAAAGCATCATCATCAAG AATGAAAAGAAGAGAAACAACCTCATTCCCATTGTTCGCTCCTTTGCTGAGGTTGGCAAGAAGCAGTCTGATCCTCATTT GATGGATAAACATGGTCAAACCGTGTCTCCTCAGTCTGTTCCAACTACAAATCTTGAAGTAAAAAATGGAGTGaATTGTG AACATAGTCCTGTGGATTTAAGCAAGGTAGACCTTCATTTCATGAAAAAAATTCCTACTGGGGCCGAGGCCTCCAATGTC CTGGTTGGAGAGGTGGATATTTTGGACCGTCCCATTGTTGCCTTTGTGAGGCTGTCTCCAGCTGTTCTTCTCTCAGGCCT AACAGAAGTGCCAATCCCAACAAGATTTTTGTTTATCTTATTGGGTCCAGTAGGGAAAGGTCAGCAGTACCATGAGATTG GCAGATCCATGGCCACCATCATGACAGATGAGATTTTTCATGACGTAGCATATAAGGCAAAAGAGCGAGATGATCTCCTG GCGGGGATTGATGAGTTCCTAGACCAGGTGACGGTGCTCCCTCCAGGAGAGTGGGATCCCTCCATTAGAATTGAGCCACC CAAAAATGTCCCTTCCCAGGAGAAAAGGAAAATGCCTGGAGTTCCAAATGGAAATGTTTGCCACATAGAACAGGAACCAC ATGGGGGTCACAGTGGGCCAGAACTTCAGCGCACTGGGCGGCTATTTGGGGGCTTGGTGCTGGACATCAAGCGGAAGGCC CCCTGGTACTGGAGCGACTACCGAGATGCACTCAGCTTACAGTGTTTGGCTTCCTTTCTGTTCCTGTACTGTGCCTGCAT GTCACCTGTCATCACCTTTGGGGGACTGCTTGGAGAAGCCACTGAGGGACGCATAAGTGCAATTGAATCCTTGTTTGGAG CTTCCATGACTGGGATTGCTTATTCCTTGTTTGCGGGACAGGCTCTCACCATCCTGGGAAGTACTGGACCAGTGCTTGTG TTTGAAAAGATTTTGTTCAAATTCTGCAAAGACTATGCTCTTTCATACCTCTCCCTGCGAGCTTGTATTGGACTGTGGAC CGCTTTCCTGTGTATTGTCCTTGTGGCAACTGATGCCAGTTCCCTTGTCTGCTACATTACCCGTTTCACTGAAGAAGCAT TTGCCTCCCTAATTTGCATTATTTTCATCTATGAAGCAATAGAAAAACTGATTCACCTGGCAGAGACCTACCCCATCCAA ATGCACAGCCAGCTGGACCACCTTAGCCTCTATTACTGCAGGTGTACTCTGCCAGAGAATCCAAACAATCACACCCTCCA GTACTGGAAGGACCACAACATCGTGACAGCAGAAGTCCACTGGGCTAACCTGACTGTCAGTGAATGCCAGGAGATGCATG GAGAGTTCATGGGATCTGCGTGCGGCCATCATGGACCCTACACTCCTGATGTCCTCTTTTGGTCCTGTATTCTCTTTTTC ACCACCTTCATCCTCTCAAGCACCTTAAAGACGTTTAAGACGAGCCGTTATTTCCCAACCAGAGTACGCTCCATGGTGAG TGACTTTGCTGTTTTCCTCACTATCTTCACAATGGTGATTATTGATTTTTTGATTGGAGTCCCATCACCAAAGCTTCAAG TTCCCAGTGTGTTCAAGCCAACAAGGGATGATCGCGGATGGATTATTAATCCCATTGGCCCCAATCCCTGGTGGACTGTG ATAGCTGCAATTATCCCAGCTCTTCTCTGTACTATCTTGATATTCATGGATCAGCAGATCACAGCCGTCATTATTAACAG GAAGGAACATAAGCTCAAGAAAGGCTGTGGCTACCACCTGGACCTACTGATGGTGGCCATCATGCTGGGTGTCTGCTCCA TCATGGGCCTGCCCTGGTTTGTAGCTGCAACTGTCTTGTCCATCACACATGTGAACAGCCTCAAGCTAGAATCTGAATGC TCTGCTCCTGGAGAACAGCCCAAGTTCCTGGGCATCCGAGAACAGAGAGTGACAGGCCTTATGATCTTTGTGCTGATGGG CTGCTCAGTCTTCATGACGGCTATCTTAAAGTTTATTCCAATGCCAGTACTCTACGGAGTTTTCCTTTACATGGGAGTTT CTTCACTACAGGGAATTCAGTTCTTTGATCGTCTAAAGCTCTTTGGGATGCCCGCAAAGCACCAGCCAGATTTCATCTAC CTGCGGCATGTGCCGCTGCGCAAAGTGCACCTCTTCACCCTCATCCAGTTGACCTGTCTCGTCCTGCTCTGGGTCATCAA GGCATCTCCAGCTGCCATTGTTTTCCCAATGATGGTTTTGGCCTTGGTCTTTGTCAGGAAAGTCATGGATCTCTGTTTCT CTAAGCGAGAGCTGAGCTGGCTAGATGATCTCATGCCTGAAAGCAAAAAGAAGAAGTTGGATGATGCCAAAAAGAAGGCC AAGGAGGAAGAGGTCATAGTCCTTGCACCAACTGTATACCTGGGGGCCTCAAATTACAGAACATAGGAAGGGTCATGTGA AAAGTCAGCATGTCTGGAATCCCGAGGGTTATATTTAGGAGCTGGGAAGATTACCCCCAAAGATGTTCTCAGCTAAGAAT GGATTAGGGATTCTTGCTTCTGTCTGTTCTTAATTTTTGGGTTTGACAACCACTTATTTTTTCCTTTGTTTACAATCTAC TCACCAGGCTCATACCTACAATGTGAACATACAGTATGCCCTTATTAGCAGATTCAATGGCTCACATTCTTTCAAAAGGT CTAATTTGACAAATACATAAGACCCATTATTTCCTAGAATGTTTGTAATATATCTAATTGCAAATGGTGCTGTGGTTGGC ACCATGCAAAGATAACTTGCATAGGACTTTCTGTCTTTTTTCATTTCCCTCAGCATTTGGCATCTTGTCATCTACACAAT GGACCCTCAATAAATGGCCTATATGTGCAAAGAAAGAATGTGTAGCAAATGAAAATACCAGACCAAGAAATGAGTGAGCT GGGAAGTGTTTCCAAATACAGTTAGTGCCTAAAATAGTGTCCTTTGAAAAAACTTTTAAAAGACTTTTTTTTAGGCCAGG CATAATGGGTTATCCCTGTAATTCCAGGGCTTTTGGGAGTTGAAGCTGGAGGATTACTTGAGGCCAGAAGTTTGAGACTA GCCTAGGCAATATAATGAGACCCTGTCTCTACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AA MKKLWWIRVGPVQFSTFTMKKKSWKTFCFFPGHRTLYVGVRMPLGRQSHRHHRTHGQKHRRRGRGKGASQGEEGLEALAH SEQ ID NO:8 DTPSQRVQFILGTEEDEEHVPHELFTELDEICMKEGEDAEWKETARWLKFEEDVEDGGERWSKPYVATLSLHSLFELRSC LINGTVLLDMHANSIEEISDLILDQQELSSDLNDSMRVKVREALLKKHHHQNEKKRNNLIPIVRSFAEVGKKQSDPHLMD KHGQTVSPQSVPTTNLEVKNGVNCEHSPVDLSKVDLHFMKKIPTGAEASNVLVGEVDILDRPIVAFVRLSPAVLLSGLTE VPIPTRFLFILLGPVGKGQQYHEIGRSMATIMTDEIFHDVAYKAKERDDLLAGIDEFLDQVTVLPPGEWDPSIRIEPPKN VPSQEKRKMPGVPNGNVCHIEQEPHGGHSGPELQRTGRLFGGLVLDIKRKAPQYWSDYRDALSLQCLASFLFLYCACMSP VITFGGLLGEATEGRISAIESLFGASMTGIAYSLFAGQALTILGSTGPVLVFEKILFKFCKDYALSYLSLRACIGLWTAF LCIVLVATDASSLVCYITRFTEEAFASLICIIFIYEAIEKLIHLAETYPIQMHSQLDHLSLYYCRCTLPENPNNHTLQYW KDHNIVTAEVHWANLTVSECQEMHGEFMGSACGHHGPYTPDVLFWSCILFFTTFILSSTLKTFKTSRYFPTRVRSMVSDF AVFLTIFTMVIIDFLIGVPSPKLQVPSVFKPTRDDRGWIINPIGPNPWWTVIAAIIPALLCTILIFMDQQITAVIINRKE HKLKKGCGYHLDLLMVAIMLGVCSIMGLPWFVAATVLSITHVNSLKLESECSAPGEQPKFLGIREQRVTGLMIFVLMGCS VFMTAILKFIPMPVLYGVFLYMGVSSLQGIQFFDRLKLFGMPAKHQPDFIYLRHVPLRKVHLFTLIQLTCLVLLWVIKAS PAAIVFPMMVLALVFVRKVMDLCFSKRELSWLDDLMPESKKKKLDDAKKKAKEEEVIVLAPTVYLGASNYRT GGACGAGGTTTGCGGGACAGGCTCTCACCATCCTGGGAAGTACTGGACCAGTGCTTGTTTTTGAAAAGATTT SEQ ID NO:9 TNTTCAAATTCTGCAAAGACTATGCTCTTTCATACCTCTCCCTGCGAGCTTGTATTGGACTGTGGACCGCTT TCCTGTGTATTGTCCTTGTGGCAACTGATGCCAGTTCCCTTGTCTGCTACATTACCCGTTTCACTGAAGAAG CATTTGCCTCCCTAATTTGCATTATTTTCATCTATGAAGCAATAGAAAAACTGATTCACCTGGCAGAGACCT ACCCCATCCACATGCACAGCCAGCTGGACCACCTTAGCCTCTATTACTGCAGGTGTACTCTGCCAGAGAATC CAAACANTCACACCCTCCAGTACTGGAAGGACCACAACATCGTGACAGCAGAAGTCCACTGGGTTAACNTGA NTGTTCATGTAAGTTTGGGNGTTGCCAGTTGTCNTAGGCNTGT Gene Name Mouse Band 3-related protein SEQ ID NO:10 Strand Score 363 Bits 168.2 Query Seq Start 463 End 581 Length 119 Blase Poisson Probabilty 1.0e-42 DB Seq Start 9 End 365 Length 357 Identity 70/119 = 58.82% Positives 86/119 = 72.27 Relative Position of Alignment: 1 |=========================================================================|970  Q: 463 FGGQPLTILSSTGPVLVFERLLFNFSKDNDFDYLEFRLWIGLWSAFQCLILVATDASFLV 522         F GQ LTIL STGPVLVFE++ F F KD    YL  R   IGLW+AF C++LVATDAS LV DB:   9 FAGQALTILGSTGPVLVFEKIXFKFCKDYALSYLSLRACIGLWTAFLCIVLVATDASSLV 188  Q: 523 KYFTRFTEEGFSSLISFIFIYDAFKKMIKLADYYPINSHFKVDYITOYSCACFPPEPAN 581          Y TRFTEE F+SLI  IFIY+A +K+I LA+ YPI+ H ++D+++ Y C C   PE  N DB: 189 CYITRFTEEAFASLICIIFIYEAIEKLIHLAETYPIHMHSQLDHLSLYYCRCTLPENPN 365 SEQ ID NO:10 refers to the sequence labelled ‘Q’

[0116]

1 10 1 3912 DNA HOMO SAPIENS 1 ttggcttgga gcccgtgggg gagacctagt tcggctccgc catgccggcc gccgggagta 60 acgagccgga cggcgtcctc agctatcaga gaccagatga agaagctgtg gtggatcagg 120 gtgggaccag tacaattctc aacattcact atgaaaaaga agagctggaa ggtcacagaa 180 ctctgtatgt gggagttcgg atgccgcttg gccggcagag ccatcggcat caccgcactc 240 atggccagaa gcaccggaga cgagggcggg gcaaaggagc cagccagggg gaggaaggcc 300 tggaagccct ggcccacgac acaccatctc agcgtgttca gttcattctt ggcaccgagg 360 aagatgaaga gcatgtgcct catgagctgt ttacagagct ggatgagatc tgtatgaaag 420 agggagaaga tgctgagtgg aaggaaacag ccaggtggct gaagtttgaa gaagatgttg 480 aagatggggg agaacgctgg agcaagcctt atgtggcaac cctttcattg cacagcctgt 540 ttgagctaag gagctgcctt attaatggaa cagtcctcct ggatatgcat gcaaatagca 600 tagaagaaat ttcagacctg atcctggatc agcaagaact gtccagtgac ctgaatgaca 660 gcatgagggt taaagtgcgg gaagcccttc tcaaaaagca tcatcatcag aatgaaaaga 720 agagaaacaa cctcattccc attgttcgct cctttgctga ggttggcaag aagcagtctg 780 atcctcattt gatggataaa catggtcaaa ccgtgtctcc tcagtctgtt ccaactacaa 840 atcttgaagt aaaaaatgga gtgaattgtg aacatagtcc tgtggattta agcaaggtag 900 accttcattt catgaaaaaa attcctactg gggccgaggc ctccaatgtc ctggttggag 960 aggtggatat tttggaccgt cccattgttg cctttgtgag gctgtctcca gctgttcttc 1020 tctcaggcct aacagaagtg ccaatcccaa caagattttt gtttatctta ttgggtccag 1080 tagggaaagg tcagcagtac catgagattg gcagatccat ggccaccatc atgacagatg 1140 agatttttca tgacgtagca tataaggcaa aagagcgaga tgatctcctg gcggggattg 1200 atgagttcct agaccaggtg acggtgctcc ctccaggaga gtgggatccc tccattagaa 1260 ttgagccacc caaaaatgtc ccttcccagg agaaaaggaa aatgcctgga gttccaaatg 1320 gaaatgtttg ccacatagaa caggaaccac atgggggtca cagtgggcca gaacttcagc 1380 gcactgggcg gctatttggg ggcttggtgc tggacatcaa gcggaaggcc ccctggtact 1440 ggagcgacta ccgagatgca ctcagcttac agtgtttggc ttcctttctg ttcctgtact 1500 gtgcctgcat gtcacctgtc atcacctttg ggggactgct tggagaagcc actgagggac 1560 gcataagtgc aattgaatcc ttgtttggag cttccatgac tgggattgct tattccttgt 1620 ttgcgggaca ggctctcacc atcctgggaa gtactggacc agtgcttgtg tttgaaaaga 1680 ttttgttcaa attctgcaaa gactatgctc tttcatacct ctccctgcga gcttgtattg 1740 gactgtggac cgctttcctg tgtattgtcc ttgtggcaac tgatgccagt tcccttgtct 1800 gctacattac ccgtttcact gaagaagcat ttgcctccct aatttgcatt attttcatct 1860 atgaagcaat agaaaaactg attcacctgg cagagaccta ccccatccaa atgcacagcc 1920 agctggacca ccttagcctc tattactgca ggtgtactct gccagagaat ccaaacaatc 1980 acaccctcca gtactggaag gaccacaaca tcgtgacagc agaagtccac tgggctaacc 2040 tgactgtcag tgaatgccag gagatgcatg gagagttcat gggatctgcg tgcggccatc 2100 atggacccta cactcctgat gtcctctttt ggtcctgtat tctctttttc accaccttca 2160 tcctctcaag caccttaaag acgtttaaga cgagccgtta tttcccaacc agagtacgct 2220 ccatggtgag tgactttgct gttttcctca ctatcttcac aatggtgatt attgattttt 2280 tgattggagt cccatcacca aagcttcaag ttcccagtgt gttcaagcca acaagggatg 2340 atcgcggatg gattattaat cccattggcc ccaatccctg gtggactgtg atagctgcaa 2400 ttatcccagc tcttctctgt actatcttga tattcatgga tcagcagatc acagccgtca 2460 ttattaacag gaaggaacat aagctcaaga aaggctgtgg ctaccacctg gacctactga 2520 tggtggccat catgctgggt gtctgctcca tcatgggcct gccctggttt gtagctgcaa 2580 ctgtcttgtc catcacacat gtgaacagcc tcaagctaga atctgaatgc tctgctcctg 2640 gagaacagcc caagttcctg ggcatccgag aacagagagt gacaggcctt atgatctttg 2700 tgctgatggg ctgctcagtc ttcatgacgg ctatcttaaa gtttattcca atgccagtac 2760 tctacggagt tttcctttac atgggagttt cttcactaca gggaattcag ttctttgatc 2820 gtctaaagct ctttgggatg cccgcaaagc accagccaga tttcatctac ctgcggcatg 2880 tgccgctgcg caaagtgcac ctcttcaccc tcatccagtt gacctgtctc gtcctgctct 2940 gggtcatcaa ggcatctcca gctgccattg ttttcccaat gatggttttg gccttggtct 3000 ttgtcaggaa agtcatggat ctctgtttct ctaagcgaga gctgagctgg ctagatgatc 3060 tcatgcctga aagcaaaaag aagaagttgg atgatgccaa aaagaaggcc aaggaggaag 3120 aggtcatagt ccttgcacca actgtatacc tgggggcctc aaattacaga acataggaag 3180 ggtcatgtga aaagtcagca tgtctggaat cccgagggtt atatttagga gctgggaaga 3240 ttacccccaa agatgttctc agctaagaat ggattaggga ttcttgcttc tgtctgttct 3300 taatttttgg gtttgacaac cacttatttt ttcctttgtt tacaatctac tcaccaggct 3360 catacctaca atgtgaacat acagtatgcc cttattagca gattcaatgg ctcacattct 3420 ttcaaaaggt ctaatttgac aaatacataa gacccattat ttcctagaat gtttgtaata 3480 tatctaattg caaatggtgc tgtggttggc accatgcaaa gataacttgc ataggacttt 3540 ctgtcttttt tcatttccct cagcatttgg catcttgtca tctacacaat ggaccctcaa 3600 taaatggcct atatgtgcaa agaaagaatg tgtagcaaat gaaaatacca gaccaagaaa 3660 tgagtgagct gggaagtgtt tccaaataca gttagtgcct aaaatagtgt cctttgaaaa 3720 aacttttaaa agactttttt ttaggccagg cataatgggt tatccctgta attccagggc 3780 ttttgggagt tgaagctgga ggattacttg aggccagaag tttgagacta gcctaggcaa 3840 tataatgaga ccctgtctct acaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3900 aaaaaaaaaa aa 3912 2 1044 PRT HOMO SAPIENS 2 Met Pro Ala Ala Gly Ser Asn Glu Pro Asp Gly Val Leu Ser Tyr Gln 1 5 10 15 Arg Pro Asp Glu Glu Ala Val Val Asp Gln Gly Gly Thr Ser Thr Ile 20 25 30 Leu Asn Ile His Tyr Glu Lys Glu Glu Leu Glu Gly His Arg Thr Leu 35 40 45 Tyr Val Gly Val Arg Met Pro Leu Gly Arg Gln Ser His Arg His His 50 55 60 Arg Thr His Gly Gln Lys His Arg Arg Arg Gly Arg Gly Lys Gly Ala 65 70 75 80 Ser Gln Gly Glu Glu Gly Leu Glu Ala Leu Ala His Asp Thr Pro Ser 85 90 95 Gln Arg Val Gln Phe Ile Leu Gly Thr Glu Glu Asp Glu Glu His Val 100 105 110 Pro His Glu Leu Phe Thr Glu Leu Asp Glu Ile Cys Met Lys Glu Gly 115 120 125 Glu Asp Ala Glu Trp Lys Glu Thr Ala Arg Trp Leu Lys Phe Glu Glu 130 135 140 Asp Val Glu Asp Gly Gly Glu Arg Trp Ser Lys Pro Tyr Val Ala Thr 145 150 155 160 Leu Ser Leu His Ser Leu Phe Glu Leu Arg Ser Cys Leu Ile Asn Gly 165 170 175 Thr Val Leu Leu Asp Met His Ala Asn Ser Ile Glu Glu Ile Ser Asp 180 185 190 Leu Ile Leu Asp Gln Gln Glu Leu Ser Ser Asp Leu Asn Asp Ser Met 195 200 205 Arg Val Lys Val Arg Glu Ala Leu Leu Lys Lys His His His Gln Asn 210 215 220 Glu Lys Lys Arg Asn Asn Leu Ile Pro Ile Val Arg Ser Phe Ala Glu 225 230 235 240 Val Gly Lys Lys Gln Ser Asp Pro His Leu Met Asp Lys His Gly Gln 245 250 255 Thr Val Ser Pro Gln Ser Val Pro Thr Thr Asn Leu Glu Val Lys Asn 260 265 270 Gly Val Asn Cys Glu His Ser Pro Val Asp Leu Ser Lys Val Asp Leu 275 280 285 His Phe Met Lys Lys Ile Pro Thr Gly Ala Glu Ala Ser Asn Val Leu 290 295 300 Val Gly Glu Val Asp Ile Leu Asp Arg Pro Ile Val Ala Phe Val Arg 305 310 315 320 Leu Ser Pro Ala Val Leu Leu Ser Gly Leu Thr Glu Val Pro Ile Pro 325 330 335 Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro Val Gly Lys Gly Gln Gln 340 345 350 Tyr His Glu Ile Gly Arg Ser Met Ala Thr Ile Met Thr Asp Glu Ile 355 360 365 Phe His Asp Val Ala Tyr Lys Ala Lys Glu Arg Asp Asp Leu Leu Ala 370 375 380 Gly Ile Asp Glu Phe Leu Asp Gln Val Thr Val Leu Pro Pro Gly Glu 385 390 395 400 Trp Asp Pro Ser Ile Arg Ile Glu Pro Pro Lys Asn Val Pro Ser Gln 405 410 415 Glu Lys Arg Lys Met Pro Gly Val Pro Asn Gly Asn Val Cys His Ile 420 425 430 Glu Gln Glu Pro His Gly Gly His Ser Gly Pro Glu Leu Gln Arg Thr 435 440 445 Gly Arg Leu Phe Gly Gly Leu Val Leu Asp Ile Lys Arg Lys Ala Pro 450 455 460 Trp Tyr Trp Ser Asp Tyr Arg Asp Ala Leu Ser Leu Gln Cys Leu Ala 465 470 475 480 Ser Phe Leu Phe Leu Tyr Cys Ala Cys Met Ser Pro Val Ile Thr Phe 485 490 495 Gly Gly Leu Leu Gly Glu Ala Thr Glu Gly Arg Ile Ser Ala Ile Glu 500 505 510 Ser Leu Phe Gly Ala Ser Met Thr Gly Ile Ala Tyr Ser Leu Phe Ala 515 520 525 Gly Gln Ala Leu Thr Ile Leu Gly Ser Thr Gly Pro Val Leu Val Phe 530 535 540 Glu Lys Ile Leu Phe Lys Phe Cys Lys Asp Tyr Ala Leu Ser Tyr Leu 545 550 555 560 Ser Leu Arg Ala Cys Ile Gly Leu Trp Thr Ala Phe Leu Cys Ile Val 565 570 575 Leu Val Ala Thr Asp Ala Ser Ser Leu Val Cys Tyr Ile Thr Arg Phe 580 585 590 Thr Glu Glu Ala Phe Ala Ser Leu Ile Cys Ile Ile Phe Ile Tyr Glu 595 600 605 Ala Ile Glu Lys Leu Ile His Leu Ala Glu Thr Tyr Pro Ile Gln Met 610 615 620 His Ser Gln Leu Asp His Leu Ser Leu Tyr Tyr Cys Arg Cys Thr Leu 625 630 635 640 Pro Glu Asn Pro Asn Asn His Thr Leu Gln Tyr Trp Lys Asp His Asn 645 650 655 Ile Val Thr Ala Glu Val His Trp Ala Asn Leu Thr Val Ser Glu Cys 660 665 670 Gln Glu Met His Gly Glu Phe Met Gly Ser Ala Cys Gly His His Gly 675 680 685 Pro Tyr Thr Pro Asp Val Leu Phe Trp Ser Cys Ile Leu Phe Phe Thr 690 695 700 Thr Phe Ile Leu Ser Ser Thr Leu Lys Thr Phe Lys Thr Ser Arg Tyr 705 710 715 720 Phe Pro Thr Arg Val Arg Ser Met Val Ser Asp Phe Ala Val Phe Leu 725 730 735 Thr Ile Phe Thr Met Val Ile Ile Asp Phe Leu Ile Gly Val Pro Ser 740 745 750 Pro Lys Leu Gln Val Pro Ser Val Phe Lys Pro Thr Arg Asp Asp Arg 755 760 765 Gly Trp Ile Ile Asn Pro Ile Gly Pro Asn Pro Trp Trp Thr Val Ile 770 775 780 Ala Ala Ile Ile Pro Ala Leu Leu Cys Thr Ile Leu Ile Phe Met Asp 785 790 795 800 Gln Gln Ile Thr Ala Val Ile Ile Asn Arg Lys Glu His Lys Leu Lys 805 810 815 Lys Gly Cys Gly Tyr His Leu Asp Leu Leu Met Val Ala Ile Met Leu 820 825 830 Gly Val Cys Ser Ile Met Gly Leu Pro Trp Phe Val Ala Ala Thr Val 835 840 845 Leu Ser Ile Thr His Val Asn Ser Leu Lys Leu Glu Ser Glu Cys Ser 850 855 860 Ala Pro Gly Glu Gln Pro Lys Phe Leu Gly Ile Arg Glu Gln Arg Val 865 870 875 880 Thr Gly Leu Met Ile Phe Val Leu Met Gly Cys Ser Val Phe Met Thr 885 890 895 Ala Ile Leu Lys Phe Ile Pro Met Pro Val Leu Tyr Gly Val Phe Leu 900 905 910 Tyr Met Gly Val Ser Ser Leu Gln Gly Ile Gln Phe Phe Asp Arg Leu 915 920 925 Lys Leu Phe Gly Met Pro Ala Lys His Gln Pro Asp Phe Ile Tyr Leu 930 935 940 Arg His Val Pro Leu Arg Lys Val His Leu Phe Thr Leu Ile Gln Leu 945 950 955 960 Thr Cys Leu Val Leu Leu Trp Val Ile Lys Ala Ser Pro Ala Ala Ile 965 970 975 Val Phe Pro Met Met Val Leu Ala Leu Val Phe Val Arg Lys Val Met 980 985 990 Asp Leu Cys Phe Ser Lys Arg Glu Leu Ser Trp Leu Asp Asp Leu Met 995 1000 1005 Pro Glu Ser Lys Lys Lys Lys Leu Asp Asp Ala Lys Lys Lys Ala Lys 1010 1015 1020 Glu Glu Glu Val Ile Val Leu Ala Pro Thr Val Tyr Leu Gly Ala Ser 1025 1030 1035 1040 Asn Tyr Arg Thr 3 2880 DNA HOMO SAPIENS 3 acagaagtgc caatcccaac aagatttttg tttatcttat tgggtccagt agggaaaggt 60 cagcagtacc atgagattgg cagatccatg gccaccatca tgacagatga gatttttcat 120 gacgtagcat ataaggcaaa agagcgagat gatctcctgg cggggattga tgagttccta 180 gaccaggtga cggtgctccc tccaggagag tgggatccct ccattagaat tgagccaccc 240 aaaaatgtcc cttcccagga gaaaaggaaa atgcctggag ttccaaatgg aaatgtttgc 300 cacatagaac aggaaccaca tgggggtcac agtgggccag aacttcagcg cactgggcgg 360 ctatttgggg gcttggtgct ggacatcaag cggaaggccc cctggtactg gagcgactac 420 cgagatgcac tcagcttaca gtgtttggct tcctttctgt tcctgtactg tgcctgcatg 480 tcacctgtca tcacctttgg gggactgctt ggagaagcca ctgagggacg cataagtgca 540 attgaatcct tgtttggagc ttccatgact gggattgctt attccttgtt tgcgggacag 600 gctctcacca tcctgggaag tactggacca gtgcttgtgt ttgaaaagat tttgttcaaa 660 ttctgcaaag actatgctct ttcatacctc tccctgcgag cttgtattgg actgtggacc 720 gctttcctgt gtattgtcct tgtggcaact gatgccagtt cccttgtctg ctacattacc 780 cgtttcactg aagaagcatt tgcctcccta atttgcatta ttttcatcta tgaagcaata 840 gaaaaactga ttcacctggc agagacctac cccatccaca tgcacagcca gctggaccac 900 cttagcctct attactgcag gtgtactctg ccagagaatc caaacaatca caccctccag 960 tactggaagg accacaacat cgtgacagca gaagtccact gggctaacct gactgtcagt 1020 gaatgccagg agatgcatgg agagttcatg ggatctgcgt gcggccatca tggaccctac 1080 actcctgatg tcctcttttg gtcctgtatt ctctttttca ccaccttcat cctctcaagc 1140 accttaaaga cgtttaagac gagccgttat ttcccaacca gagtacgctc catggtgagt 1200 gactttgctg ttttcctcac tatcttcaca atggtgatta ttgatttttt gattggagtc 1260 ccatcaccaa agcttcaagt tcccagtgtg ttcaagccaa caagggatga tcgcggatgg 1320 attattaatc ccattggccc caatccctgg tggactgtga tagctgcaat tatcccagct 1380 cttctctgta ctatcttgat attcatggat cagcagatca cagccgtcat tattaacagg 1440 aaggaacata agctcaagaa aggctgtggc taccacctgg acctactgat ggtggccatc 1500 atgctgggtg tctgctccat catgggcctg ccctggtttg tagctgcaac tgtcttgtcc 1560 atcacacatg tgaacagcct caagctagaa tctgaatgct ctgctcctgg agaacagccc 1620 aagttcctgg gcatccgaga acagagagtg acaggcctta tgatctttgt gctgatgggc 1680 tgctcagtct tcatgacggc tatcttaaag tttattccaa tgccagtact ctacggagtt 1740 ttcctttaca tgggagtttc ttcactacag ggaattcagt tctttgatcg tctaaagctc 1800 tttgggatgc ccgcaaagca ccagccagat ttcatctacc tgcggcatgt gccgctgcgc 1860 aaagtgcacc tcttcaccct catccagttg acctgtctcg tcctgctctg ggtcatcaag 1920 gcatctccag ctgccattgt tttcccaatg atggttttgg ccttggtctt tgtcaggaaa 1980 gtcatggatc tctgtttctc taagcgagag ctgagctggc tagatgatct catgcctgaa 2040 agcaaaaaga agaagttgga tgatgccaaa aagaaggcca aggaggaaga ggtcatagtc 2100 cttgcaccaa ctgtatacct gggggcctca aattacagaa cataggaagg gtcatgtgaa 2160 aagtcagcat gtctggaatc ccgagggtta tatttaggag ctgggaagat tacccccaaa 2220 gatgttctca gctaagaatg gattagggat tcttgcttct gtctgttctt aatttttggg 2280 tttgacaacc acttattttt tcctttgttt acaatctact caccaggctc atacctacaa 2340 tgtgaacata cagtatgccc ttattagcag attcaatggc tcacattctt tcaaaaggtc 2400 taatttgaca aatacataag acccattatt tcctagaatg tttgtaatat atctaattgc 2460 aaatggtgct gtggttggca ccatgcaaag ataacttgca taggactttc tgtctttttt 2520 catttccctc agcatttggc atcttgtcat ctacacaatg gaccctcaat aaatggccta 2580 tatgtgcaaa gaaagaatgt gtagcaaatg aaaataccag accaagaaat gagtgagctg 2640 ggaagtgttt ccaaatacag ttagtgccta aaatagtgtc ctttgaaaaa acttttaaaa 2700 gacttttttt taggccaggc ataatgggtt atccctgtaa ttccagggct tttgggagtt 2760 gaagctggag gattacttga ggccagaagt ttgagactag cctaggcaat ataatgagac 2820 cctgtctcta caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2880 4 714 PRT HOMO SAPIENS 4 Thr Glu Val Pro Ile Pro Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro 1 5 10 15 Val Gly Lys Gly Gln Gln Tyr His Glu Ile Gly Arg Ser Met Ala Thr 20 25 30 Ile Met Thr Asp Glu Ile Phe His Asp Val Ala Tyr Lys Ala Lys Glu 35 40 45 Arg Asp Asp Leu Leu Ala Gly Ile Asp Glu Phe Leu Asp Gln Val Thr 50 55 60 Val Leu Pro Pro Gly Glu Trp Asp Pro Ser Ile Arg Ile Glu Pro Pro 65 70 75 80 Lys Asn Val Pro Ser Gln Glu Lys Arg Lys Met Pro Gly Val Pro Asn 85 90 95 Gly Asn Val Cys His Ile Glu Gln Glu Pro His Gly Gly His Ser Gly 100 105 110 Pro Glu Leu Gln Arg Thr Gly Arg Leu Phe Gly Gly Leu Val Leu Asp 115 120 125 Ile Lys Arg Lys Ala Pro Trp Tyr Trp Ser Asp Tyr Arg Asp Ala Leu 130 135 140 Ser Leu Gln Cys Leu Ala Ser Phe Leu Phe Leu Tyr Cys Ala Cys Met 145 150 155 160 Ser Pro Val Ile Thr Phe Gly Gly Leu Leu Gly Glu Ala Thr Glu Gly 165 170 175 Arg Ile Ser Ala Ile Glu Ser Leu Phe Gly Ala Ser Met Thr Gly Ile 180 185 190 Ala Tyr Ser Leu Phe Ala Gly Gln Ala Leu Thr Ile Leu Gly Ser Thr 195 200 205 Gly Pro Val Leu Val Phe Glu Lys Ile Leu Phe Lys Phe Cys Lys Asp 210 215 220 Tyr Ala Leu Ser Tyr Leu Ser Leu Arg Ala Cys Ile Gly Leu Trp Thr 225 230 235 240 Ala Phe Leu Cys Ile Val Leu Val Ala Thr Asp Ala Ser Ser Leu Val 245 250 255 Cys Tyr Ile Thr Arg Phe Thr Glu Glu Ala Phe Ala Ser Leu Ile Cys 260 265 270 Ile Ile Phe Ile Tyr Glu Ala Ile Glu Lys Leu Ile His Leu Ala Glu 275 280 285 Thr Tyr Pro Ile His Met His Ser Gln Leu Asp His Leu Ser Leu Tyr 290 295 300 Tyr Cys Arg Cys Thr Leu Pro Glu Asn Pro Asn Asn His Thr Leu Gln 305 310 315 320 Tyr Trp Lys Asp His Asn Ile Val Thr Ala Glu Val His Trp Ala Asn 325 330 335 Leu Thr Val Ser Glu Cys Gln Glu Met His Gly Glu Phe Met Gly Ser 340 345 350 Ala Cys Gly His His Gly Pro Tyr Thr Pro Asp Val Leu Phe Trp Ser 355 360 365 Cys Ile Leu Phe Phe Thr Thr Phe Ile Leu Ser Ser Thr Leu Lys Thr 370 375 380 Phe Lys Thr Ser Arg Tyr Phe Pro Thr Arg Val Arg Ser Met Val Ser 385 390 395 400 Asp Phe Ala Val Phe Leu Thr Ile Phe Thr Met Val Ile Ile Asp Phe 405 410 415 Leu Ile Gly Val Pro Ser Pro Lys Leu Gln Val Pro Ser Val Phe Lys 420 425 430 Pro Thr Arg Asp Asp Arg Gly Trp Ile Ile Asn Pro Ile Gly Pro Asn 435 440 445 Pro Trp Trp Thr Val Ile Ala Ala Ile Ile Pro Ala Leu Leu Cys Thr 450 455 460 Ile Leu Ile Phe Met Asp Gln Gln Ile Thr Ala Val Ile Ile Asn Arg 465 470 475 480 Lys Glu His Lys Leu Lys Lys Gly Cys Gly Tyr His Leu Asp Leu Leu 485 490 495 Met Val Ala Ile Met Leu Gly Val Cys Ser Ile Met Gly Leu Pro Trp 500 505 510 Phe Val Ala Ala Thr Val Leu Ser Ile Thr His Val Asn Ser Leu Lys 515 520 525 Leu Glu Ser Glu Cys Ser Ala Pro Gly Glu Gln Pro Lys Phe Leu Gly 530 535 540 Ile Arg Glu Gln Arg Val Thr Gly Leu Met Ile Phe Val Leu Met Gly 545 550 555 560 Cys Ser Val Phe Met Thr Ala Ile Leu Lys Phe Ile Pro Met Pro Val 565 570 575 Leu Tyr Gly Val Phe Leu Tyr Met Gly Val Ser Ser Leu Gln Gly Ile 580 585 590 Gln Phe Phe Asp Arg Leu Lys Leu Phe Gly Met Pro Ala Lys His Gln 595 600 605 Pro Asp Phe Ile Tyr Leu Arg His Val Pro Leu Arg Lys Val His Leu 610 615 620 Phe Thr Leu Ile Gln Leu Thr Cys Leu Val Leu Leu Trp Val Ile Lys 625 630 635 640 Ala Ser Pro Ala Ala Ile Val Phe Pro Met Met Val Leu Ala Leu Val 645 650 655 Phe Val Arg Lys Val Met Asp Leu Cys Phe Ser Lys Arg Glu Leu Ser 660 665 670 Trp Leu Asp Asp Leu Met Pro Glu Ser Lys Lys Lys Lys Leu Asp Asp 675 680 685 Ala Lys Lys Lys Ala Lys Glu Glu Glu Val Ile Val Leu Ala Pro Thr 690 695 700 Val Tyr Leu Gly Ala Ser Asn Tyr Arg Thr 705 710 5 385 DNA HOMO SAPIENS UNSURE (126)(127)(321)(347)(352)(371)(383) 5 acagaagtgc caatcccaac aagatttttg tttatcttat tgggtccagt agggaaaggt 60 cagcagtacc atgagattgg cagatccatg gccaccatca tgacagatga gatttttcat 120 gacgtnncat ataaggcaaa agagcgagat gatctcctgg cggggattga tgagttccta 180 gaccaggtga cggtgctccc tccaggagag tgggatccct ccattagaat tgagccaccc 240 aaaaatgtcc cttcccagga gaaaaggaaa atgcctggaa gttccaaatg gaaatgtttg 300 ccacatagaa caggaaccac ngggggtcac atgggccaga acttcancgc anggggcggc 360 tatttggggg nttggtggct ggnac 385 6 254 PRT HOMO SAPIENS UNSURE (152) 6 Gln Thr Glu Val Pro Val Pro Thr Arg Phe Leu Phe Ile Leu Leu Gly 1 5 10 15 Pro Lys Gly Lys Ala Lys Ser Tyr His Glu Ile Gly Arg Ser Ile Ala 20 25 30 Thr Leu Met Ser Asp Glu Val Phe His Asp Ile Ala Tyr Lys Ala Lys 35 40 45 Asn Arg Glu Asp Leu Ile Ala Gly Ile Asp Glu Phe Leu Thr Glu Val 50 55 60 Pro Pro Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro Gly Lys Tyr His 65 70 75 80 Glu Ile Gly Arg Ser Ala Thr Met Asp Glu Phe His Asp Tyr Lys Ala 85 90 95 Lys Arg Asp Leu Ala Gly Ile Asp Glu Phe Leu Asp Asx Thr Glu Val 100 105 110 Pro Ile Pro Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro Val Gly Lys 115 120 125 Gly Gln Gln Tyr His Glu Ile Gly Arg Ser Met Ala Thr Ile Met Thr 130 135 140 Asp Glu Ile Phe His Asp Val Xaa Tyr Lys Ala Lys Glu Arg Asp Asp 145 150 155 160 Leu Leu Ala Gly Ile Asp Glu Phe Leu Gln Asp Glu Val Ile Val Leu 165 170 175 Pro Leu Gly Glu Trp Asp Pro Thr Ile Arg Ile Glu Pro Pro Lys Ser 180 185 190 Leu Pro Ser Ser Asp Lys Arg Lys Asp Val Val Leu Pro Gly Glu Trp 195 200 205 Asp Pro Ile Arg Ile Glu Pro Pro Lys Pro Ser Lys Arg Lys Asp Asx 210 215 220 Asp Gln Val Thr Val Leu Pro Pro Gly Glu Trp Asp Pro Ser Ile Arg 225 230 235 240 Ile Glu Pro Pro Lys Asn Val Pro Ser Gln Glu Lys Arg Lys 245 250 7 3842 DNA HOMO SAPIENS 7 agaccagatg aagaagctgt ggtggatcag ggtgggacca gtacaattct caacattcac 60 tatgaaaaag aagagctgga agaccttctg cttctttcca ggtcacagaa ctctgtatgt 120 gggagttcgg atgccgcttg gccggcagag ccatcggcat caccgcactc atggccagaa 180 gcaccggaga cgagggcggg gcaaaggagc cagccagggg gaggaaggcc tggaagccct 240 ggcccacgac acaccatctc agcgtgttca gttcattctt ggcaccgagg aagatgaaga 300 gcatgtgcct catgagctgt ttacagagct ggatgagatc tgtatgaaag agggagaaga 360 tgctgagtgg aaggaaacag ccaggtggct gaagtttgaa gaagatgttg aagatggggg 420 agaacgctgg agcaagcctt atgtggcaac cctttcattg cacagcctgt ttgagctaag 480 gagctgcctt attaatggaa cagtcctcct ggatatgcat gcaaatagca tagaagaaat 540 ttcagacctg atcctggatc agcaagaact gtccagtgac ctgaatgaca gcatgagggt 600 taaagtgcgg gaagcccttc tcaaaaagca tcatcatcag aatgaaaaga agagaaacaa 660 cctcattccc attgttcgct cctttgctga ggttggcaag aagcagtctg atcctcattt 720 gatggataaa catggtcaaa ccgtgtctcc tcagtctgtt ccaactacaa atcttgaagt 780 aaaaaatgga gtgaattgtg aacatagtcc tgtggattta agcaaggtag accttcattt 840 catgaaaaaa attcctactg gggccgaggc ctccaatgtc ctggttggag aggtggatat 900 tttggaccgt cccattgttg cctttgtgag gctgtctcca gctgttcttc tctcaggcct 960 aacagaagtg ccaatcccaa caagattttt gtttatctta ttgggtccag tagggaaagg 1020 tcagcagtac catgagattg gcagatccat ggccaccatc atgacagatg agatttttca 1080 tgacgtagca tataaggcaa aagagcgaga tgatctcctg gcggggattg atgagttcct 1140 agaccaggtg acggtgctcc ctccaggaga gtgggatccc tccattagaa ttgagccacc 1200 caaaaatgtc ccttcccagg agaaaaggaa aatgcctgga gttccaaatg gaaatgtttg 1260 ccacatagaa caggaaccac atgggggtca cagtgggcca gaacttcagc gcactgggcg 1320 gctatttggg ggcttggtgc tggacatcaa gcggaaggcc ccctggtact ggagcgacta 1380 ccgagatgca ctcagcttac agtgtttggc ttcctttctg ttcctgtact gtgcctgcat 1440 gtcacctgtc atcacctttg ggggactgct tggagaagcc actgagggac gcataagtgc 1500 aattgaatcc ttgtttggag cttccatgac tgggattgct tattccttgt ttgcgggaca 1560 ggctctcacc atcctgggaa gtactggacc agtgcttgtg tttgaaaaga ttttgttcaa 1620 attctgcaaa gactatgctc tttcatacct ctccctgcga gcttgtattg gactgtggac 1680 cgctttcctg tgtattgtcc ttgtggcaac tgatgccagt tcccttgtct gctacattac 1740 ccgtttcact gaagaagcat ttgcctccct aatttgcatt attttcatct atgaagcaat 1800 agaaaaactg attcacctgg cagagaccta ccccatccaa atgcacagcc agctggacca 1860 ccttagcctc tattactgca ggtgtactct gccagagaat ccaaacaatc acaccctcca 1920 gtactggaag gaccacaaca tcgtgacagc agaagtccac tgggctaacc tgactgtcag 1980 tgaatgccag gagatgcatg gagagttcat gggatctgcg tgcggccatc atggacccta 2040 cactcctgat gtcctctttt ggtcctgtat tctctttttc accaccttca tcctctcaag 2100 caccttaaag acgtttaaga cgagccgtta tttcccaacc agagtacgct ccatggtgag 2160 tgactttgct gttttcctca ctatcttcac aatggtgatt attgattttt tgattggagt 2220 cccatcacca aagcttcaag ttcccagtgt gttcaagcca acaagggatg atcgcggatg 2280 gattattaat cccattggcc ccaatccctg gtggactgtg atagctgcaa ttatcccagc 2340 tcttctctgt actatcttga tattcatgga tcagcagatc acagccgtca ttattaacag 2400 gaaggaacat aagctcaaga aaggctgtgg ctaccacctg gacctactga tggtggccat 2460 catgctgggt gtctgctcca tcatgggcct gccctggttt gtagctgcaa ctgtcttgtc 2520 catcacacat gtgaacagcc tcaagctaga atctgaatgc tctgctcctg gagaacagcc 2580 caagttcctg ggcatccgag aacagagagt gacaggcctt atgatctttg tgctgatggg 2640 ctgctcagtc ttcatgacgg ctatcttaaa gtttattcca atgccagtac tctacggagt 2700 tttcctttac atgggagttt cttcactaca gggaattcag ttctttgatc gtctaaagct 2760 ctttgggatg cccgcaaagc accagccaga tttcatctac ctgcggcatg tgccgctgcg 2820 caaagtgcac ctcttcaccc tcatccagtt gacctgtctc gtcctgctct gggtcatcaa 2880 ggcatctcca gctgccattg ttttcccaat gatggttttg gccttggtct ttgtcaggaa 2940 agtcatggat ctctgtttct ctaagcgaga gctgagctgg ctagatgatc tcatgcctga 3000 aagcaaaaag aagaagttgg atgatgccaa aaagaaggcc aaggaggaag aggtcatagt 3060 ccttgcacca actgtatacc tgggggcctc aaattacaga acataggaag ggtcatgtga 3120 aaagtcagca tgtctggaat cccgagggtt atatttagga gctgggaaga ttacccccaa 3180 agatgttctc agctaagaat ggattaggga ttcttgcttc tgtctgttct taatttttgg 3240 gtttgacaac cacttatttt ttcctttgtt tacaatctac tcaccaggct catacctaca 3300 atgtgaacat acagtatgcc cttattagca gattcaatgg ctcacattct ttcaaaaggt 3360 ctaatttgac aaatacataa gacccattat ttcctagaat gtttgtaata tatctaattg 3420 caaatggtgc tgtggttggc accatgcaaa gataacttgc ataggacttt ctgtcttttt 3480 tcatttccct cagcatttgg catcttgtca tctacacaat ggaccctcaa taaatggcct 3540 atatgtgcaa agaaagaatg tgtagcaaat gaaaatacca gaccaagaaa tgagtgagct 3600 gggaagtgtt tccaaataca gttagtgcct aaaatagtgt cctttgaaaa aacttttaaa 3660 agactttttt ttaggccagg cataatgggt tatccctgta attccagggc ttttgggagt 3720 tgaagctgga ggattacttg aggccagaag tttgagacta gcctaggcaa tataatgaga 3780 ccctgtctct acaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3840 aa 3842 8 1032 PRT HOMO SAPIENS 8 Met Lys Lys Leu Trp Trp Ile Arg Val Gly Pro Val Gln Phe Ser Thr 1 5 10 15 Phe Thr Met Lys Lys Lys Ser Trp Lys Thr Phe Cys Phe Phe Pro Gly 20 25 30 His Arg Thr Leu Tyr Val Gly Val Arg Met Pro Leu Gly Arg Gln Ser 35 40 45 His Arg His His Arg Thr His Gly Gln Lys His Arg Arg Arg Gly Arg 50 55 60 Gly Lys Gly Ala Ser Gln Gly Glu Glu Gly Leu Glu Ala Leu Ala His 65 70 75 80 Asp Thr Pro Ser Gln Arg Val Gln Phe Ile Leu Gly Thr Glu Glu Asp 85 90 95 Glu Glu His Val Pro His Glu Leu Phe Thr Glu Leu Asp Glu Ile Cys 100 105 110 Met Lys Glu Gly Glu Asp Ala Glu Trp Lys Glu Thr Ala Arg Trp Leu 115 120 125 Lys Phe Glu Glu Asp Val Glu Asp Gly Gly Glu Arg Trp Ser Lys Pro 130 135 140 Tyr Val Ala Thr Leu Ser Leu His Ser Leu Phe Glu Leu Arg Ser Cys 145 150 155 160 Leu Ile Asn Gly Thr Val Leu Leu Asp Met His Ala Asn Ser Ile Glu 165 170 175 Glu Ile Ser Asp Leu Ile Leu Asp Gln Gln Glu Leu Ser Ser Asp Leu 180 185 190 Asn Asp Ser Met Arg Val Lys Val Arg Glu Ala Leu Leu Lys Lys His 195 200 205 His His Gln Asn Glu Lys Lys Arg Asn Asn Leu Ile Pro Ile Val Arg 210 215 220 Ser Phe Ala Glu Val Gly Lys Lys Gln Ser Asp Pro His Leu Met Asp 225 230 235 240 Lys His Gly Gln Thr Val Ser Pro Gln Ser Val Pro Thr Thr Asn Leu 245 250 255 Glu Val Lys Asn Gly Val Asn Cys Glu His Ser Pro Val Asp Leu Ser 260 265 270 Lys Val Asp Leu His Phe Met Lys Lys Ile Pro Thr Gly Ala Glu Ala 275 280 285 Ser Asn Val Leu Val Gly Glu Val Asp Ile Leu Asp Arg Pro Ile Val 290 295 300 Ala Phe Val Arg Leu Ser Pro Ala Val Leu Leu Ser Gly Leu Thr Glu 305 310 315 320 Val Pro Ile Pro Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro Val Gly 325 330 335 Lys Gly Gln Gln Tyr His Glu Ile Gly Arg Ser Met Ala Thr Ile Met 340 345 350 Thr Asp Glu Ile Phe His Asp Val Ala Tyr Lys Ala Lys Glu Arg Asp 355 360 365 Asp Leu Leu Ala Gly Ile Asp Glu Phe Leu Asp Gln Val Thr Val Leu 370 375 380 Pro Pro Gly Glu Trp Asp Pro Ser Ile Arg Ile Glu Pro Pro Lys Asn 385 390 395 400 Val Pro Ser Gln Glu Lys Arg Lys Met Pro Gly Val Pro Asn Gly Asn 405 410 415 Val Cys His Ile Glu Gln Glu Pro His Gly Gly His Ser Gly Pro Glu 420 425 430 Leu Gln Arg Thr Gly Arg Leu Phe Gly Gly Leu Val Leu Asp Ile Lys 435 440 445 Arg Lys Ala Pro Trp Tyr Trp Ser Asp Tyr Arg Asp Ala Leu Ser Leu 450 455 460 Gln Cys Leu Ala Ser Phe Leu Phe Leu Tyr Cys Ala Cys Met Ser Pro 465 470 475 480 Val Ile Thr Phe Gly Gly Leu Leu Gly Glu Ala Thr Glu Gly Arg Ile 485 490 495 Ser Ala Ile Glu Ser Leu Phe Gly Ala Ser Met Thr Gly Ile Ala Tyr 500 505 510 Ser Leu Phe Ala Gly Gln Ala Leu Thr Ile Leu Gly Ser Thr Gly Pro 515 520 525 Val Leu Val Phe Glu Lys Ile Leu Phe Lys Phe Cys Lys Asp Tyr Ala 530 535 540 Leu Ser Tyr Leu Ser Leu Arg Ala Cys Ile Gly Leu Trp Thr Ala Phe 545 550 555 560 Leu Cys Ile Val Leu Val Ala Thr Asp Ala Ser Ser Leu Val Cys Tyr 565 570 575 Ile Thr Arg Phe Thr Glu Glu Ala Phe Ala Ser Leu Ile Cys Ile Ile 580 585 590 Phe Ile Tyr Glu Ala Ile Glu Lys Leu Ile His Leu Ala Glu Thr Tyr 595 600 605 Pro Ile Gln Met His Ser Gln Leu Asp His Leu Ser Leu Tyr Tyr Cys 610 615 620 Arg Cys Thr Leu Pro Glu Asn Pro Asn Asn His Thr Leu Gln Tyr Trp 625 630 635 640 Lys Asp His Asn Ile Val Thr Ala Glu Val His Trp Ala Asn Leu Thr 645 650 655 Val Ser Glu Cys Gln Glu Met His Gly Glu Phe Met Gly Ser Ala Cys 660 665 670 Gly His His Gly Pro Tyr Thr Pro Asp Val Leu Phe Trp Ser Cys Ile 675 680 685 Leu Phe Phe Thr Thr Phe Ile Leu Ser Ser Thr Leu Lys Thr Phe Lys 690 695 700 Thr Ser Arg Tyr Phe Pro Thr Arg Val Arg Ser Met Val Ser Asp Phe 705 710 715 720 Ala Val Phe Leu Thr Ile Phe Thr Met Val Ile Ile Asp Phe Leu Ile 725 730 735 Gly Val Pro Ser Pro Lys Leu Gln Val Pro Ser Val Phe Lys Pro Thr 740 745 750 Arg Asp Asp Arg Gly Trp Ile Ile Asn Pro Ile Gly Pro Asn Pro Trp 755 760 765 Trp Thr Val Ile Ala Ala Ile Ile Pro Ala Leu Leu Cys Thr Ile Leu 770 775 780 Ile Phe Met Asp Gln Gln Ile Thr Ala Val Ile Ile Asn Arg Lys Glu 785 790 795 800 His Lys Leu Lys Lys Gly Cys Gly Tyr His Leu Asp Leu Leu Met Val 805 810 815 Ala Ile Met Leu Gly Val Cys Ser Ile Met Gly Leu Pro Trp Phe Val 820 825 830 Ala Ala Thr Val Leu Ser Ile Thr His Val Asn Ser Leu Lys Leu Glu 835 840 845 Ser Glu Cys Ser Ala Pro Gly Glu Gln Pro Lys Phe Leu Gly Ile Arg 850 855 860 Glu Gln Arg Val Thr Gly Leu Met Ile Phe Val Leu Met Gly Cys Ser 865 870 875 880 Val Phe Met Thr Ala Ile Leu Lys Phe Ile Pro Met Pro Val Leu Tyr 885 890 895 Gly Val Phe Leu Tyr Met Gly Val Ser Ser Leu Gln Gly Ile Gln Phe 900 905 910 Phe Asp Arg Leu Lys Leu Phe Gly Met Pro Ala Lys His Gln Pro Asp 915 920 925 Phe Ile Tyr Leu Arg His Val Pro Leu Arg Lys Val His Leu Phe Thr 930 935 940 Leu Ile Gln Leu Thr Cys Leu Val Leu Leu Trp Val Ile Lys Ala Ser 945 950 955 960 Pro Ala Ala Ile Val Phe Pro Met Met Val Leu Ala Leu Val Phe Val 965 970 975 Arg Lys Val Met Asp Leu Cys Phe Ser Lys Arg Glu Leu Ser Trp Leu 980 985 990 Asp Asp Leu Met Pro Glu Ser Lys Lys Lys Lys Leu Asp Asp Ala Lys 995 1000 1005 Lys Lys Ala Lys Glu Glu Glu Val Ile Val Leu Ala Pro Thr Val Tyr 1010 1015 1020 Leu Gly Ala Ser Asn Tyr Arg Thr 1025 1030 9 475 DNA HOMO SAPIENS UNSURE (74)(367)(429)(433)(452)(466)(472) 9 ggacgaggtt tgcgggacag gctctcacca tcctgggaag tactggacca gtgcttgttt 60 ttgaaaagat tttnttcaaa ttctgcaaag actatgctct ttcatacctc tccctgcgag 120 cttgtattgg actgtggacc gctttcctgt gtattgtcct tgtggcaact gatgccagtt 180 cccttgtctg ctacattacc cgtttcactg aagaagcatt tgcctcccta atttgcatta 240 ttttcatcta tgaagcaata gaaaaactga ttcacctggc agagacctac cccatccaca 300 tgcacagcca gctggaccac cttagcctct attactgcag gtgtactctg ccagagaatc 360 caaacantca caccctccag tactggaagg accacaacat cgtgacagca gaagtccact 420 gggttaacnt gantgttcat gtaagtttgg gngttgccag ttgtcntagg cntgt 475 10 314 PRT HOMO SAPIENS UNSURE (124) 10 Gln Phe Gly Gly Gln Pro Leu Thr Ile Leu Ser Ser Thr Gly Pro Val 1 5 10 15 Leu Val Phe Glu Arg Leu Leu Phe Asn Phe Ser Lys Asp Asn Asp Phe 20 25 30 Asp Tyr Leu Glu Phe Arg Leu Trp Ile Gly Leu Trp Ser Ala Phe Gln 35 40 45 Cys Leu Ile Leu Val Ala Thr Asp Ala Ser Phe Leu Val Phe Gly Gln 50 55 60 Leu Thr Ile Leu Ser Thr Gly Pro Val Leu Val Phe Glu Phe Phe Lys 65 70 75 80 Asp Tyr Leu Arg Ile Gly Leu Trp Ala Phe Cys Leu Val Ala Thr Asp 85 90 95 Ala Ser Leu Val Asp Asx Phe Ala Gly Gln Ala Leu Thr Ile Leu Gly 100 105 110 Ser Thr Gly Pro Val Leu Val Phe Glu Lys Ile Xaa Phe Lys Phe Cys 115 120 125 Lys Asp Tyr Ala Leu Ser Tyr Leu Ser Leu Arg Ala Cys Ile Gly Leu 130 135 140 Trp Thr Ala Phe Leu Cys Ile Val Leu Val Ala Thr Asp Ala Ser Ser 145 150 155 160 Leu Val Gln Lys Tyr Phe Thr Arg Phe Thr Glu Glu Gly Phe Ser Ser 165 170 175 Leu Ile Ser Phe Ile Phe Ile Tyr Asp Ala Phe Lys Lys Met Ile Lys 180 185 190 Leu Ala Asp Tyr Tyr Pro Ile Asn Ser His Phe Lys Val Asp Tyr Ile 195 200 205 Thr Gln Tyr Ser Cys Ala Cys Phe Pro Pro Glu Pro Ala Asn Tyr Thr 210 215 220 Arg Phe Thr Glu Glu Phe Ser Leu Ile Ile Phe Ile Tyr Ala Lys Ile 225 230 235 240 Leu Ala Tyr Pro Ile His Asp Tyr Cys Cys Pro Glu Asn Asp Asx Cys 245 250 255 Tyr Ile Thr Arg Phe Thr Glu Glu Ala Phe Ala Ser Leu Ile Cys Ile 260 265 270 Ile Phe Ile Tyr Glu Ala Ile Glu Lys Leu Ile His Leu Ala Glu Thr 275 280 285 Tyr Pro Ile His Met His Ser Gln Leu Asp His Leu Ser Leu Tyr Tyr 290 295 300 Cys Arg Cys Thr Leu Pro Glu Asn Pro Asn 305 310 

What is claimed is:
 1. An isolated polypeptide selected from the group consisting of: (i) an isolated polypeptide comprising an amino acid sequence selected from the group having at least: (a) 70% identity, (b) 80% identity; (c) 90% identity; or (d) 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2; (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2 or (iii) an isolated polypeptide which is the amino acid sequence of SEQ ID NO:2. (iv) an isolated polypeptide comprising an amino acid sequence selected from the group having at least: (a) 70% identity, (b) 80% identity; (c) 90% identity; or (d) 95% identity to the amino acid sequence of SEQ ID NO:8 over the entire length of SEQ ID NO:8; (v) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:8 or (vi) an isolated polypeptide which is the amino acid sequence of SEQ ID NO:8.
 2. An isolated polynucleotide selected from the group consisting of: (i) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least (a) 70% identity; (b) 80% identity; (c) 90% identity; or (d) 95% identity; to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2; (ii) an isolated polynucleotide comprising a nucleotide sequence that has at least: (a) 70% identity (b) 80% identity; (c) 90% identity; or (d) 95% identity; over its entire length to a nucleotide sequence encoding the polypeptide of SEQ ID NO:2; (iii) an isolated polynucleotide comprising a nucleotide sequence which has at least: (a) 70% identity; (b) 80% identity; (c) 90% identity; or (d) 95% identity; to that of SEQ ID NO:1 over the entire length of SEQ ID NO:1; (iv) an isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2; (v) an isolated polynucleotide which is the polynucleotide of SEQ ID NO:1; or (vi) an isolated polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.; or a nucleotide sequence complementary to said isolated polynucleotide.
 3. An isolated polynucleotide selected from the group consisting of: (i) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least (a) 70% identity; (b) 80% identity; (c) 90% identity; or (d) 95% identity; to the amino acid sequence of SEQ ID NO:8, over the entire length of SEQ ID NO:8; (ii) an isolated polynucleotide comprising a nucleotide sequence that has at least: (a) 70% identity (b) 80% identity; (c) 90% identity; or (d) 95% identity; over its entire length to a nucleotide sequence encoding the polypeptide of SEQ ID NO:8; (iii) an isolated polynucleotide comprising a nucleotide sequence which has at least: (a) 70% identity; (b) 80% identity; (c) 90% identity; or (d) 95% identity; to that of SEQ ID NO:7 over the entire length of SEQ ID NO:7; (iv) an isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:8; (vi) an isolated polynucleotide which is the polynucleotide of SEQ ID NO:7; or (vi) an isolated polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 7 or a fragment thereof.; or a nucleotide sequence complementary to said isolated polynucleotide.
 4. An antibody immunospecific for the polypeptide of claim 1 .
 5. A method for the treatment of a subject: (i) in need of enhanced activity or expression of the polypeptide of claim I comprising: (a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and/or (b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence encoding said polypetide in a form so as to effect production of said polypeptide activity in vivo.; or (ii) having need to inhibit activity or expression of the polypeptide of claim 1 comprising: (a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or (b) administering to the subject a nucleic acid molecule that inhibits the expression of a nucleotide sequence encoding said polypeptide; and/or (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate, or receptor.
 6. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the polypeptide of claim 1 in a subject comprising: (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and/or (b) analyzing for the presence or amount of said polypeptide expression in a sample derived from said subject.
 7. A method for screening to identify compounds which stimulate or which inhibit the function of the polypeptide of claim 1 which comprises a method selected from the group consisting of: (a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound; (b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competition; (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide; (d) mixing a candidate compound with a solution containing a polypeptide of claim 1 , to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay.
 8. An agonist or an antagonist of the polypeptide of claim 1 .
 9. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression system is present in a compatible host cell.
 10. A process for producing a recombinant host cell comprising transforming or transfecting a cell with the expression system of claim 9 such the the host cell, under appropriate culture conditions, produces a polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2; and (b) a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:8 over the entire length of SEQ ID NO:8.
 11. A recombinant host cell produced by the process of claim 10 .
 12. A membrane of a recombinant host cell of claim 11 expressing a polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2; and (b) a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:8 over the entire length of SEQ ID NO:8.
 13. A process for producing a polypeptide comprising culturing a host cell of claim 11 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
 14. An isolated polynucleotide selected form the group consisting of (a) an isolated polynucleotide comprising a nucleotide sequence which has at least 70%, 80%, 90%, 95%, 97% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3; (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:3; (c) the polynucleotide of SEQ ID NO:3; or (d) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 70%,80%, 90%, 95%, 97-99% identity to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4. (e) an isolated polynucleotide comprising a nucleotide sequence which has at least 70%, 80%, 90%, 95%, 97% identity to SEQ ID NO:5 over the entire length of SEQ ID NO:5; (f) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:5: (g) the polynucleotide of SEQ ID NO:5; or (h) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 70%,80%, 90%, 95%, 97-99% identity to the amino acid sequence of SEQ ID NO:6, over the entire length of SEQ ID NO:6; or (i) an isolated polynucleotide comprising a nucleotide sequence which has at least 70%, 80%, 90%, 95%, 97% identity to SEQ ID NO:9 over the entire length of SEQ ID NO:9; (j) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:9; (k) the polynucleotide of SEQ ID NO:9; or (l) an isolated polvnucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 70%,80%, 90%, 95%, 97-99% identity to the amino acid sequence of SEQ ID NO:10, over the entire length of SEQ ID NO:10.
 15. A polypeptide selected from the group consisting of (a) a polypeptide which comprises an amino acid sequence which has at least 70%,80%,90%, 95%, 97-99% identity to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4; (b) a polypeptide which has an amino acid sequence which is at least 70%, 80%, 90%, 95%, 97-99% identity to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4; (c) a polypeptide which comprises the amino acid of SEQ ID NO:4; (d) a polypeptide which is the polypeptide of SEQ ID NO:4; or (e) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3. (f) a polypeptide which comprises an amino acid sequence which has at least 70%,80%,90%, 95%, 97-99% identity to that of SEQ ID NO:6 over the entire length of SEQ ID NO:6; (g) a polypeptide which has an amino acid sequence which is at least 70%, 80%, 90%, 95%, 97-99% identity to the amino acid sequence of SEQ ID NO:6 over the entire length of SEQ ID NO:6; (h) a polypeptide which comprises the amino acid of SEQ ID NO:6; (i) a polypeptide which is the polypeptide of SEQ ID NO:6; or (j) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:5; or (k) a polypeptide which comprises an amino acid sequence which has at least 70%,80%,90%, 95%, 97-99% identity to that of SEQ ID NO:10 over the entire length of SEQ ID NO:10; (l) a polypeptide which has an amino acid sequence which is at least 70%, 80%, 90%, 95%, 97-99% identity to the amino acid sequence of SEQ ID NO:10 over the entire length of SEQ ID NO:10; (m) a polypeptide which comprises the amino acid of SEQ ID NO:10; (n) a polypeptide which is the polypeptide of SEQ ID NO:10; or (o) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:9. 